CURRICULUM VITAE. NAME: Kyoo-Rok Han, M.D., Ph.D. (Professor) ADDRESS:

Transcription

1 CURRICULUM VITAE NAME: Kyoo-Rok Han, M.D., Ph.D. (Professor) ADDRESS: Div. of Cardiology, Dept. of Internal Medicine College of Medicine, Hallym University, Kangdong Sacred Heart Hospital, 445 Kil-Dong, Kangdong-Gu, Seoul , Korea Phone: , 2405 Fax: krheart@hallym.or.kr EDUCATION: 1986 M.D. College of Medicine, Seoul National University 1995 M.S. Internal Medicine, Seoul National University 2004 Ph.D. College of Medicine, Gyeongsang National University PROFESSIONAL ACTIVITIES: Internship, Seoul National University Hospital Residency, Seoul National University Hospital, Internal Medicine Fellowship, Seoul National University Hospital, Cardiology Instructor, Cardiology, Kangdong Sacred Heart Hospital, Assistant Professor, Cardiology, Kangdong Sacred Heart Hospital, Visiting Scholar, Vascular Medicine, University of California San Diego Associate Professor, Cardiology, Kangdong Sacred Heart Hospital, 2006-present Professor, Cardiology, Kangdong Sacred Heart Hospital, 2011-present Head, Cardiovascular Center, Kangdong Sacred Heart Hospital, FIELDS OF INTEREST: 1. Atherosclerosis & Coronary Artery Desease 2. Acute Coronary Syndrome & ST-Elevation Myocardial Infarction 3. Trans-Radial Approach in Percutaneous Coronary Intervention 4. Heart Care Network Program SOCIETIES:

2 1. Member, Korean Association of Internal Medicine 2. Member, Korean Society of Circulation 3. Member, Korean Society of Atherosclerosis 4. Councilor, Korean Society of Interventional Cardiology 5. Chairman, Committee of Data Monitoring and Management, Korea Working Group on Myocardial Infarction 6. Member, Committee of Insurance Policy, Korean Society of Circulation 7. Councilor, Korean Society of Circulation 8. Vice Chairman, Committee on Division of Cardiology Korean Association of Internal Medicine 9. Chairman, Committee of General Affairs, Korea Working Group on Trans-Radial Intervention 10. Director, Department of General Affairs, Korean Society of Interventional Cardiology ONGOING PROJECTS IN 2011: CHOONGWAE PHARMA [10-004] Observational study of LIVALO tab for research of safety information by concomitant administration with antihypertensive agents. 8,625,000won / 8,625,000won (2011) KUHNIL PHARM [10-016] Multicenter, open, registry study to cardiovascular efficacy of Omacor (omega-3-fatty acids) in patients with Myocardical Infarction. 5,520,000won / 5,520,000won (2011) BAYER [10-017] A prospective observational study of clinical outcomes following acute myocardial infarction in type 2 diabetic patients. 7,000,000won / 7,000,000won (2011) DIO CORPORATION [10-020] A trial of evaluation additional benefit of cilostazol to dual antiplatelet therapy patients with long or multi-vessel coronary artery disease underwent BioMatrixTM stent implantation (ABCD trial) 5,175,000won / 5,175,000won (2011) DIO CORPORATION [10-021] Biolimus-3000 korea Registry 1,725,000won / 1,725,000won (2010) CHONG KUN DANG PHARMACEUTICAL [10-042] A randomized, double-blind, multi-center, multi-factorial, phase 2 trial to evaluate the efficacy and safety of S-amlodipine/Telmisartan combined or alone and select better dose of CKD-828 in patients with essential hypertension 25,336,240won / 25,336,240won (2011)

3 HANMI PHARMACEUTICAL [10-052] An eight-week, randomized, double-blind multicenter study to compare the efficacy and safety of Amosartan tab 5/100mg versus Cozaar plus pro tab in patients with essential hypertension uncontrolled with Losartan 100mg monotherapy 16,215,000won / 16,215,000won (2011) SEOUL NATIONAL UNIVERSITY HOSPITAL [10-058] Comparison of the Efficacy and Safety of new platform Everolimus-eluting coronary stent system (Promus Element) with Zotarolimus-eluting coronary stent system (Endeavor Resolute) and triple anti-platelet therapy with double-dose clopidogrel anti-platelet therapy in patients with Coronary Heart Disease - Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - SAfety & EffectiveneSS of Drug - ElUting Stents & Anti-platelet REgimen (HOST-ASSURE trial) 10,000,000won / 10,000,000won (2011) SY MEDICARE [10-071] Biolimus-3000 korea Registry 5,000,000won / 5,000,000won (2011) CARDIO VASCULAR RESEARCH FOUNDATION [10-074] Evaluation of Effectiveness and Safety of PROMUS ElementTM in Routine Clinical Practice; A Multicenter, PROSPECTIVE OBSERVATIONAL STUDY 1,285,714won / 1,285,714won (2011) CARDIO VASCULAR RESEARCH FOUNDATION [10-086] Evaluation of Effectiveness and Safety of Endothelial progenitor cell capture stents (GENOUS BIO-ENGINEERED R stent TM in Primary Stenting for ST-elevation Acute Myocardial Infarction :A Munticenter, phase_iv, Prospective Observational Study) 1,500,000won / 1,500,000won (2011) FOUNDATION FOR INDUSTRY COOPERATION, UNIVERSITY OF ULSAN [10-090] IRIS-MAIN : a global, multicenter, prospective, real world observational study for left main disease treatment 2,083,333won / 2,083,333won (2011) MERCK [10-099] A prospective, multicentre, open-label, single arm observational study of Concor treatment in Asian Patients with Essential hypertension 1,451,875won / 1,451,875won (2011) JUNG SUNG MEDICAL [10-087] Comparison of the efficacy and safety of Endothelial progenitor cell capture stents (GENOUS BIO-ENGINEERED R stent TM) With 1 month dual anti-platelet therapy versus 3 months dual anti-platelet therapy in patients with Coronary lesion in real

4 world practice ( GIO-STUDY) 11,500,000won / 11,500,000won (2011) SHINAE MEDICAL [10-116] Harmonized optimal strategy for treatment of genous bioengineered R stent in ischemic Heart disease 5,000,000won / 5,000,000won (2011) AJOU UNIVERSITY HOSPITAL [10-117] Comparison of Biolimus-eluting biodegradable polymer, everolimus-eluting and Sirolimus-eluting coronary Stents (BESS-trial) 9,000,000won / 9,000,000won (2011) HANMI PHARMACEUTICAL [11-012] Efficacy and Safety of Coadministered Irbesartan and Atrovastatin in Patients with Hypertension and Hyperlipidemia: A Randomized, Double-blind, Factorial, Multicenter, Phase 3 study 48,500,000won / 48,500,000won (2011) ISU ABXIS [11-016] Clotinab application in high risk Acute Coronary syndrome undergoing PCI (CAP Regirstry) 20,000,000won / 20,000,000won (2011) CHOONGWAE PHARMA [11-020] A Randomized, Placebo controlled Phase III Trial to Evaluate the Efficacy, Safety of Coadimistered Pitavastatin and Valsartan in patients with hypertension and Dyslipidemia. 33,120,000won / 33,120,000won (2011) MSD [11-027] Re-examination study for general drug use to assess the safety and efficacy profile of TREDAPTIVE tablet in usual practice 718,750won / 718,750won (2011) CHONG KUN DANG PHARMACEUTICAL [11-067] A Randomized, Double-blind, Multicenter, Phase 3 Trial to Evaluate the Efficancy and safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) versus Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy 14,702,351won / 14,702,351won (2011) CARDIO VASCULAR RESEARCH FOUNDATION [11-068] A Multicenter, prospective cohort to evaluate the natural history of FFR guided deferred lesions (IRIS-FFR DEFER Registry) 3,450,000won / 3,450,000won (2011)

5 ASTRAZENECA [11-075] EPICOR-Aisa. Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients in Asia. 6,708,333won / 6,708,333won (2011) I.R.I.S [11-082] Effects of ivabradine in patients with stable coronary disease without clinical heart failure. A randomised double-blind placebo-controlled international multicenter study. Study assessing the morbi-mortality benefits of the If inhibitor ivabradine in patients with coronary arterly disease(signify) 11,545,810won / 11,545,810won (2011) MEDTRONIC [11-090] Randomized Inverstigation to Verify clinical Efficacy and safety comparing Endeavor Tesolute Integrity and Biolimus A9-elutingstentin acute coronary syndrome patients. 7,500,000won / 7,500,000won (2011) CARDIO VASCULAR RESEARCH FOUNDATION [11-091] Evaluation of effectiveness and safety of Resolute Integrity DES in Routine Clinical Practice; A multicenter prospective observational cohort study 1,475,000won / 1,475,000won (2011) NOVARTIS [10-001] A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction 2,800,000won / 31,200,000won (2011) DAIICHI SANKYO [10-114] To observe adherence between patient with SEVIKAR TAB. (Fixed Dose Combination) and Calcium channel blocker + Angiotensin II - Receptor Blocker (Free Combination) bitherapy in usual clinical settings. 200,000won / 5,000,000won (2011) Orbusneich Korea [11-094] Endothellal progenitor cell capture stent with 1month dual antiplatelet therapy versus everolomus-elting stent with standard 12month dual antiplatelet therapy in elderly( 70year) with stable coronary disease INNOVATION Trail 1,000,000won / 4,166,667won (2011) IV. KCI Accredited Journal (Candidated Journal for Accreditation); Co-author 1. SH Lee, KR Han, DJ Oh, A Case of Mobile Thrombus in Ascending Aorta as an Embolic Source of Stroke. Korean Journal of Medicine Vol. 80( ), PP. 152~156, SI Seo, KR Han, DJ Oh, High Cardiac Output Heart Failure Induced by Chronic Severe Anemia. Korean Journal of Medicine Vol. 81(3), PP. 378~381, 2011